Viral antigen presented by human cytomegalovirus

The designation "Viral antigen presented by human cytomegalovirus" is not itself a specific molecular entity or therapeutic target. Instead, it generically refers to the diverse viral proteins produced by human cytomegalovirus (HCMV) that are processed inside infected cells and presented on the cell surface by host major histocompatibility complex (MHC) class I or II molecules as antigens. These viral antigens can arise from numerous HCMV proteins, including envelope glycoproteins such as glycoprotein B (gB), glycoprotein H (gH), proteins in the US family responsible for immune evasion (such as US2, US3, US6), and many others[1][2][3][4][5][6][7]. Individual antigens are targets for host immune responses, notably for cytotoxic T lymphocyte (CTL) surveillance, and are not a singular protein or structure. Key HCMV viral antigens of clinical or research importance are usually named more specifically, such as "Human cytomegalovirus glycoprotein B (gB)", "Human cytomegalovirus glycoprotein H (gH)", or "Human cytomegalovirus UL83 (pp65)"[1][4][5][7]. If a precise target molecule is required for structured data, the particular viral protein of interest should be specified instead of the generic term "viral antigen presented by human cytomegalovirus." **Caveat:** The input "Viral antigen presented by human cytomegalovirus" is too broad, does not map to a unique protein target, and cannot be directly considered a canonical therapeutic target as defined in molecular pharmacology or immunology. Instead, it encompasses a family of specific protein targets, each with distinct biology, and can only be properly structured at the level of specific antigens like "Human cytomegalovirus glycoprotein B" (gB) or "Human cytomegalovirus UL83" (pp65)[1][4][5][7].

Other names

Human cytomegalovirus antigenHCMV antigenCytomegalovirus antigen